ArticleCancer communications (London, England)2018

Safety and efficacy of obinutuzumab in Chinese patients with B-cell lymphomas: a secondary analysis of the GERSHWIN trial.

Yan Qin et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.